晚期早产生长受限妊娠产前皮质激素效果
单中心回顾性队列纳入247例晚期早产生长受限或小于胎龄儿妊娠,比较未用激素与接受倍他米松者的新生儿结局。主要复合呼吸结局两组无显著差异(16.2% vs 12.5%,P=.41),但新生儿低血糖在激素暴露组更常见(40.4% vs 25.2%,P=.012)。
要点
- 晚期早产生长受限妊娠使用产前皮质激素未显著减少新生儿呼吸支持需求
- 激素暴露组新生儿低血糖(<40 mg/dL)发生率更高
- 该特殊人群可能无法从晚期早产皮质激素中获益
核心结论
- 晚期早产生长受限妊娠使用产前皮质激素未显著降低新生儿呼吸支持需求,且新生儿低血糖增加,该人群可能不获益。
研究设计与样本
- 单中心回顾性队列研究,纳入247例晚期早产生长受限妊娠,111例未用激素,136例接受晚期早产倍他米松。
主要发现
- 主要复合结局两组无差异(16.2% [18/111] vs 12.5% [17/136];P=.41),校正产次与子痫前期后 adjusted odds ratio 0.63(P=.29);新生儿低血糖(<40 mg/dL)激素组更高(40.4% [55/136] vs 25.2% [28/111];P=.012)。
关键数值与推荐
- 生长受限定义为胎儿生长受限诊断或出生体重小于10%的小于胎龄儿;主要复合结局含 CPAP 或高流量鼻导管≥2小时、FiO2≥30%吸氧≥4小时、任何机械通气、死产或新生儿死亡;P<.05 为显著。
临床怎么用
- 对晚期早产生长受限妊娠决定是否使用产前皮质激素时,应权衡呼吸获益不显著与新生儿低血糖风险增加。
局限性
- 单中心回顾性设计;激素组无产次与子痫前期分布差异(P=.01、P=.001),可能受混杂影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recently, the Antenatal Late Preterm Steroids study reported that antenatal corticosteroids administered in the late preterm period (34.0-36.6 weeks' gestation) reduced the rate of neonatal respiratory complications at birth. The utility of this intervention in women with fetal growth restriction remains unclear. OBJECTIVE: This study aimed to determine whether administration of antenatal corticosteroids in the late preterm period in pregnancies with growth restriction decreased the need for respiratory support at delivery and other neonatal morbidities. STUDY DESIGN: This was a single-center retrospective cohort study that included growth-restricted pregnancies delivered in the late preterm period. Growth restriction was defined as either a diagnosis of fetal growth restriction or small for gestational age by birthweight less than 10%. The primary composite outcome consisted of any 1 of the following occurring in a single neonate: requirement of continuous positive airway pressure or high-flow nasal cannula for 2 hours or more, oxygen requirement with fraction of inspired oxygen of ≥30% for 4 hours or more, mechanical ventilation at any time, stillbirth, or neonatal death. The primary outcome was compared between steroid naive pregnancies and pregnancies exposed to betamethasone in the late preterm period. Univariable and multivariable statistical analysis was performed and P<.05 was considered statistically significant. RESULTS: A total of 247 women with a diagnosis of growth restriction or small for gestational age met all inclusion criteria, 111 of whom did not receive antenatal corticosteroids and 136 received late preterm antenatal corticosteroids. Demographics were similar between the groups, with the exception of those who received betamethasone being more likely to be nulliparous (P=.01) and to receive a diagnosis of preeclampsia (P=.001). The primary outcome did not differ between the 2 groups (16.2% [18/111] vs 12.5% [17/136]; P=.41). Multivariable modeling controlling for parity and preeclampsia indicated that the rate of the primary composite respiratory outcome was similar between the exposure groups (adjusted odds ratio, 0.63; P=.29). Neonatal hypoglycemia (<40 mg/dL) was more common in newborns exposed to steroids (25.2% [28 /111] vs 40.4% [55/136]; P=.012). CONCLUSION: Administration of antenatal corticosteroids in the late preterm period for pregnancies with growth restriction did not significantly decrease the need for respiratory support in newborns at our institution. The rate of neonatal hypoglycemia increased after exposure to antenatal corticosteroids. This special population may not benefit from late preterm steroids.
引用
- Bitar G, Merrill SJ, Sciscione AC, et al. Antenatal corticosteroids in the late preterm period for growth-restricted pregnancies. Am J Obstet Gynecol MFM. 2020. PMID: 33345883. doi:10.1016/j.ajogmf.2020.100153
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。